0ec02d90-7ccb-476e-a8bb-9a9c8f158dee
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- COMPLEMENT+0.400
- IL2_STAT5_SIGNALING+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- PANCREAS_BETA_CELLS+0.400
- COAGULATION+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
Top 10 suppressed
- ANDROGEN_RESPONSE-0.300
- G2M_CHECKPOINT-0.300
- MITOTIC_SPINDLE-0.300
- PROTEIN_SECRETION-0.300
- UV_RESPONSE_DN-0.300
- WNT_BETA_CATENIN_SIGNALING-0.300
- E2F_TARGETS-0.200
- ESTROGEN_RESPONSE_EARLY-0.200
- MYC_TARGETS_V1-0.200
- NOTCH_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R13 | — | — | 0.864 |
| 2 | TCGA-FD-A5BS-01A-21R-A26T-07 | — | — | 0.862 |
| 3 | SRR8518127 | — | D | 0.844 |
| 4 | TCGA-BH-A0B6-01A-11R-A19W-07 | — | D | 0.843 |
| 5 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.837 |
| 6 | TCGA-50-5045-01A-01R-1628-07 | — | cohortA1 | 0.829 |
| 7 | ad2bbb19-6d02-480f-b011-d4327c3c5607 | — | — | 0.829 |
| 8 | TCGA-55-8208-01A-11R-2241-07 | — | cohortMD2 | 0.828 |
| 9 | TCGA-E2-A1LH-01A-11R-A14D-07 | — | E | 0.827 |
| 10 | TCGA-E2-A14Z-01A-11R-A115-07 | — | D | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.400 | Cobimetinib | — uncovered |
| COAGULATION | 0.300 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.100 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |